The pharma wars continue as telehealth disruptors like Hims & Hers encroach on the market share of long-established drugmakers. A new campaign from Eli Lilly, which sells FDA-approved injectable GLP-1 drugs Mounjaro and Zepbound, appears to target such smaller brands without explicitly calling them out by name.